Data Science & Artificial Intelligence

Artificial Intelligence

ÐǺ£ÆåÅÆ is using data science and AI to turbocharge innovation and transform how it researches, develops and commercializes novel antibody therapies with the goal to make an impact on the lives of patients.
View of amber, nebulous cells through a microscopic lensView of amber, nebulous cells through a microscopic lens

Harnessing the power of AI

The integration of AI into the biotech industry has the potential to revolutionize healthcare by accelerating drug discovery, optimizing clinical trials, tailoring treatments and effectively bringing medicines to the market. ÐǺ£ÆåÅÆ is at the forefront of this transformation, harnessing the power of AI aiming to bring new therapies and solutions to market faster than ever before.

A woman in business attire sits in a booth working on her laptop.

How we use AI

AI enhances how we identify disease targets, clinical biomarker candidates and biological insights. And it scales and automates the derivation of novel antibody discoveries in ways that were not possible before.

We use AI to integrate and analyze complex data from different stages of the drug development process to transform our understanding of cancer and other serious diseases, and discover insights on how to match the right treatment to the right patient at right time and at the right dose.

AI helps our Discovery team to streamline and accelerate how we identify targets and design product candidates. The team is experimenting with ways to embed in silico approaches in the design of innovative antibody product candidates, which we anticipate will make it possible to identify promising candidate medicines faster and with higher quality.
Diagram showing various types of cells: adaptive immune cells, connective tissue cells, cancer cells and innate immune cells
Using AI we are able to combine huge datasets of many patients that give us detailed insight into the cellular makeup of cancer.
AI-generated visuals of human protein sequences.
AI predictions on sequence of all 30,000 human proteins. Cell surface (dark blue) vs. intra-cellular (light blue). Using AI, we can more effectively predict characteristics of drugs and targets without lab experiments, purely based on their sequence.
Innovation
ÐǺ£ÆåÅÆ Launches “AI Everywhereâ€
19 September 2024
ÐǺ£ÆåÅÆ embraces ChatGPT Enterprise, supported by OpenAI’s commitment to security and privacy
Read Story

Transforming trials and collaboration

A microscope slide of blue cells against a black background
Optimizing clinical trials
Clinical trials are essential for evaluating the safety and efficacy of new treatments. Yet they can be lengthy, costly and challenging. ÐǺ£ÆåÅÆ is using AI to optimize the clinical trials process, applying the technology to help identify suitable patient populations, streamline the recruitment process, and design and execute trials more efficiently.
Three people gather around a table working on a laptop.
Collaboration and knowledge sharing
ÐǺ£ÆåÅÆ is building strategic AI technology alliances with other companies and academic organizations to enhance its AI capabilities. We have partnered with the world’s leading technology companies to enable access to enterprise-grade versions of the most capable large language models (LLMs). This places multimodal AI capabilities at the fingertips of ÐǺ£ÆåÅÆ colleagues. It is creating 'citizen data scientists' who are unleashing their curiosity and experimentation to enhance and at times re-imagine how they work.
Explore further
A scientist closely examines a petri dish in a modern lab environment.

Antibody Technology Platforms

Amber-colored cells in a microscope lens

Pipeline

Colorful textured cells in a microscope lens

Approved Medicines